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INTRODUCTION
It is important to distinguish the pathogenic mechanisms
involved in the onset and progression of diabetes mellitus, one of
the most common metabolic diseases in humans. Hyperglycemia
causes many of the pathological consequences of both type 1 and
type 2 diabetes. The main consequences of hyperglycemia of
particular pathological relevance are 1) formation, auto-
oxidation, and interaction with cell receptors of advanced
glycation end products; 2) activation of various isoforms of
protein kinase C; 3) induction of the polyol (sorbitol) pathway;
4) and increased hexosamine pathway flux (1). Enhanced
oxidative stress and declines in antioxidant capacity are
considered to play important roles in the pathogenesis of chronic
diabetes mellitus and its complications (2, 3). Reactive oxygen
species (ROS) may serve as second messengers in the insulin
action cascade (redox paradox) (4). Glucose and lipid
metabolism are largely dependent on the mitochondrial
functional state and physiology. ROS formation by
mitochondria, excessive mitochondrial oxidative damage and
reduced mitochondria biogenesis contribute to mitochondria
disruption, and, subsequently, to insulin resistance and
associated diabetic complications (5-7). The realization that
mitochondria are at the intersection of aerobic cellular life and
death has made them a promising target for drug discovery and
therapeutic interventions (8). As was recently discussed,
hyperglycemia induced mitochondrial dysfunction in liver holds
importance in the context of non-alcoholic fatty liver disease in
diabetic subjects (9).
The administration of succinic acid (50 mg/kg) as a
bioenergetic regulator corrects oxidative phosphorylation
disturbances in hepatic mitochondria under diabetes in rats and
reduces blood glucose and cholesterol (10). Succinate protected
isolated rat liver mitochondria from peroxidative damage,
proteins from cross-links, mitochondrial membranes from
permeability changes (11). The known antioxidant, pineal gland
hormone, melatonin, has both receptor-dependent and
independent mechanisms (12). Many of the beneficial effects of
melatonin administration may depend on its action on the
mitochondria (13, 14). Earlier we documented some beneficial
effects of melatonin under experimental diabetes in rats:
correction of impaired antioxidative status in liver tissue and
regulation of nitric oxide bioavailability in the aorta (15). Long-
term melatonin administration to diabetic rats reduced their
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Mitochondrial dysfunction and an increase in mitochondrial reactive oxygen species in response to hyperglycemia
during diabetes lead to pathological consequences of hyperglycemia. The aim of the present work was to investigate the
role of a specific functional damage in rat liver mitochondria during diabetes as well as to evaluate the possibility of
metabolic and antioxidative correction of mitochondrial disorders by pharmacological doses of succinate and melatonin.
In rat liver mitochondria, streptozotocin-induced diabetes was accompanied by marked impairments of metabolism: we
observed a significant activation of α-ketoglutarate dehydrogenase (by 60%, p<0.05) and a damage of the respiratory
function. In diabetic animals, melatonin (10 mg/kg b.w., 30 days) or succinate (50 mg/kg b.w., 30 days) reversed the
oxygen consumption rate V3 and the acceptor control ratio to those in nondiabetic animals. Melatonin enhanced the
inhibited activity of catalase in the cytoplasm of liver cells and prevented mitochondrial glutathione-S-transferase
inhibition while succinate administration prevented α-ketoglutarate dehydrogenase activation. The mitochondria
dysfunction associated with diabetes was partially remedied by succinate or melatonin administration. Thus, these
molecules may have benefits for the treatment of diabetes. The protective mechanism may be related to improvements
in mitochondrial physiology and the antioxidative status of cells.
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hyperlipidemia and hyperinsulinemia and enhanced insulin-
receptor kinase and insulin receptor substrate-1 phosphorylation;
this suggests the existence of a signaling pathway cross-talk
between melatonin and insulin (16).
The aim of the present work was to investigate the role of a
specific functional damage in rat liver mitochondria during
diabetes as well as to evaluate the possibility of mitochondrial
impairment corrections by the energetic substrate, succinate, and
by the antioxidant, melatonin.
MATERIAL AND METHODS
Chemicals
Melatonin, 5,5’-dithiobis(2-nitrobenzoic acid) (Ellman’s
reagent), succinic acid disodium salt hexahydrate, reduced
glutathione (GSH), trichloroacetic acid (TCA), 2,6-
dichlorophenol-indophenol, tert-butyl hydroperoxide (tBHP),
1-chloro-2,4-dinitrobenzene (CDNB) and safranin O were from
Sigma-Aldrich (St. Louis, MO, USA/Steinheim, Germany).
Streptozotocin (Streptozocin) (STZ) was from Fluka Chemie
AG (Buchs, Switzerland). All other reagents were of analytical
grade and were purchased from Reakhim (Moscow, Russia). All
the water solutions were made with water purified in the Milli-
Q system.
Animal model
The investigations were performed using 60 male albino
Wistar rats (150-180 g). A standard balanced diet and tap
water were provided ad libitum. Lights were on daily from
08.00 to 20.00 h. Ten animals received physiological saline
containing 5% ethanol intraperitoneally (i.p.) and were kept as
controls. Experimental animals were injected with a single
dose of STZ (45 mg/kg, i.p.), dissolved in 0.01 M citrate
buffer, pH 4.5, immediately before use. Seven days later,
blood glucose levels were determined in whole blood samples.
The rats injected with STZ were considered diabetic if their
fasting blood glucose was >200 mg/dL (Blood Glucose Sensor
Electrodes, MediSense, Abbot Laboratories, Bedford, UK).
The first subgroup of the hyperglycemic animals diagnosed
was injected daily with physiological saline containing 5%
ethanol (i.p.) (the diabetes group); the second subgroup
received daily 10 mg melatonin/kg b.w. (i.p.) (diabetes+10 mg
melatonin); the third subgroup received daily 50 mg
succinate/kg b.w. (i.p.) (diabetes+50 mg succinate); and the
fourth subgroup received daily 10 mg melatonin/kg b.w.+50
mg succinate/kg b.w (i.p.) (diabetes+10 mg melatonin+50 mg
succinate). Melatonin was prepared as a 0.3% solution in
physiological saline, containing 5% ethanol, and succinate
was prepared as a 1.0% solution in physiological saline.
Melatonin as well as succinate was injected in the morning at
08.00; thus, we evaluated the effect of exogenous melatonin
administration that was used as an antioxidant. The rats were
sacrificed after 30 days of melatonin and succinate (or saline)
administration. Melatonin (10 mg/kg) (15, 17) and succinate
(50 mg/kg) (10) were administered at doses that were applied
earlier. The animals were killed by decapitation according to
the rules of the European Convention for the Protection of
Vertebrate Animals Used for Experimental and Other
Scientific Purposes and the study was approved by the Ethics
Committee of the Institute for Pharmacology and
Biochemistry of the National Academy of Sciences of Belarus.
Blood samples were drawn by an abdominal aorta puncture
into tubes containing hirudin (50 µg/ml). After removing of
plasma by centrifugation, the erythrocytes were washed three
times with cold phosphate buffered saline (150 mM NaCl, 
10 mM Na2HPO4, pH 7.4).
Isolation of rat liver mitochondria
Mitochondria were isolated by differential centrifugation
from the liver as follows (18). The liver was quickly removed
and was homogenized in a glass-Teflon homogenizer with ice-
cold isolation medium containing 250 mM sucrose, 20 mM Tris-
HCl and 1 mM EDTA, pH 7.2, at 2°C. The homogenate was
centrifuged at 600 g for 10 min, and the supernatant was
centrifuged at 8,500 g for 10 min. The obtained pellet was
washed in buffer containing 250 mM sucrose, 20 mM Tris-HCl,
pH 7.2 (at 2°C). The protein concentration was determined by
the method of Lowry et al. (19). Respiration of mitochondria
was measured using a laboratory-made oxygen Clark-type
electrode and a hermetic polarographic cell (volume 1.25 ml)
with constant gentle stirring. The incubation medium contained
50 mM sucrose, 20 mM Tris-HCl, 125 mM KCl, 2.5 mM
KH2PO4, 5 mM MgSO4, 0.5 mM EDTA, pH 7.5. The
experiments were performed at 25°C using 5 mM succinate or L-
glutamate as substrates. The mitochondrial protein concentration
in the probe was 1.0 mg/ml. The functional state of mitochondria
was determined by the acceptor control ratio (ACR), equal to the
ratio of the respiratory rates (V3/V2) of mitochondria in states 3
and 2, and the coefficient of phosphorylation (ADP/O). State 2
corresponded to the respiration in the presence of the substrate
(glutamate, or succinate) added (V2), and the rate of
mitochondrial respiration corresponding to state 3 (V3) was
registered after addition of 180 µM ADP (in the presence of 
210 nm ADP in the polarographic cell).
Biochemical measurements
A stable form of glycated haemoglobin (GHb) containing 
1-deoxy-1(N-valyl)fructose and the activities of marker enzymes
of hepatic cell membrane injury, alanine aminotransferase (ALT)
and aspartate aminotransferase (AST) were assayed in blood
plasma using a reagent kits from Pliva-Lachema (Brno, Czech
Republic). The concentration of total and protein thiols in
mitochondria was determined spectrophotometrically by the
method of Ellman (20) using the molar absorption coefficient 
ε 412 =1.36·104 M–1·cm–1. Mixed disulfides (PSSG) formed by
glutathione and accessible sulfhydryl groups of mitochondrial
proteins were determined by the method described by Rossi et al.
(21). The level of accumulated lipid peroxidation products
(thiobarbituric acid-reactive substances, TBARS) was
determined according to Stocks and Dormandy (22).
α-Ketoglutarate dehydrogenase (KGDH) activity was
assayed as the rate of NAD reduction that was measured
spectrophotometrically at 340 nm upon addition of fractured
mitochondria (by rapid freezing-thawing of mitochondria,
three times) to the medium containing 0.1 M potassium
phosphate buffer, pH 7.4, 5.0 mM MgCl2, 40.0 µM rotenone,
2.5 mM α-ketoglutarate, 0.1 mM CoA, 0.2 mM thiamine
pyrophosphate, and 1.0 mM NAD at 25°C (23). The protein
concentration in the reaction mixture was 50 µg/ml. The
activity of mitochondrial succinate dehydrogenase (SDH) was
spectrophotometrically determined by the rate of 2,6-
dichlorophenol-indophenol reduction at 600 nm upon addition
of fractured mitochondria (final protein concentration of 50
µg/ml) to the reaction mixture containing 0.1 M potassium
phosphate buffer, pH 7.4, 25 mM sodium succinate, 0.5 mM
phenazinemetasulfate, 2.5 mM sodium azide, 0.05 mM 
2,6-dichlorophenol-indophenol (23).
Mitochondrial glutathione peroxidase (GPx) activity was
measured by the rate of GSH oxidation according to the method
422
of Martinez et al. (24). The reaction mixture contained 0.1 M
Tris-HCl, pH 7.0, 1 mM EDTA, 12 mM sodium azide, 2 mM
tBHP and 4.9 mM GSH (as cosubstrates of GPx). The reaction
was started by addition of fractured mitochondria and was
stopped by 0.2 ml 25% TCA after 10-min incubation at 37°C.
The protein concentration in the reaction mixture was 100
µg/ml. The activity was measured as the amount of GSH
oxidized in the GPx reaction using Ellman’s reagent.
The activity of mitochondrial glutathione-S-transferase
(GST) was determined employing the method of Habig et al.
(25). The reactions were carried out in the presence of 10 µg
mitochondrial protein, 1 mM CDNB (as substrate), 5 mM GSH
and 100 mM potassium phosphate buffer, pH 6.5, at 25°C in the
final volume of 2 ml. The conjugation of CDNB with glutathione
was monitored at 340 nm, using the molar absorbtion coefficient
of 9,600 M-1cm-1.
Catalase activity was measured in rat liver cell cytoplasm by
the method of Aebi (26). The reaction mixture contained 
4.5 µg/ml protein, 20 mM hydrogen peroxide (H2O2), 50 mM
potassium phosphate buffer, pH 7.0. The H2O2 decomposition
was monitored at 240 nm by the use of the molar absorption
coefficient of 36 M-1cm-1 and at 25°C for 3 min.
Statistical analysis
Data for 8-10 rats in each group are presented as a mean
±S.E.M. We used the standard unpaired Student t test for the
comparison of the data, p<0.05 was taken to indicate statistical
significance.
RESULTS
Biochemical impairments and oxidative stress under diabetes
In our experiments, 30-day STZ-induced diabetes mellitus in
rats resulted in elevated levels of blood glucose and glycosylated
haemoglobin as well as in reduction of animal body weight
(Table 1). Similarly, the activities of the markers of liver
damage, ALT and AST, in rat blood plasma increased by 50%
(p<0.01) and 10% (p<0.05), respectively (Table 1). Succinate,
but not melatonin, administration to diabetic animals reduced
hepatolysis, diminishing elevated blood plasma ALT and AST
activities. Diabetes resulted in significant impairments of rat
tissues and organs: the kidney weight / body weight ratio
increased in diabetic rats (Table 1). In our experiments, the
melatonin injection to diabetic animals, but not succinate or
melatonin plus succinate, recovered this parameter to the control
value (p<0.01 in comparison with the diabetic animals) but did
not affect body weight (Table 1). The level of lipid peroxidation
products (TBARS) increased in the heart (by 20%, p<0.05) but
not in the liver tissues of diabetic rats. The melatonin (but not
succinate) administration prevented elevation of TBARS levels
in heart tissue (Table 2). The melatonin or succinate (or both)
administration to diabetic rats reduced the hepatic TBARS levels
(p<0.05 in comparison with diabetes) (Table 2). The level of
reduced glutathione decreased in red blood cells (by 25%,
p<0.05) (Table 2). The liver mitochondrial protein thiol group
content and mitochondrial total thiol group content did not
change as a result of diabetes (Table 2). The level of PSSG
increased in mitochondria of diabetic rats (by 50%, p<0.05). We
evaluated the activities of antioxidative and glutathione
metabolizing enzymes: liver mitochondrial GPx activity (did not
change), liver mitochondrial GST activity (the main detoxifying
enzyme) (decreased by 12%, p<0.05) and cytoplasmic catalase
activity (decreased by 45%, p<0.001). Thus, the activities of the
enzymatic antioxidative defense system diminished in the liver
of diabetic rats (Table 2). Melatonin administration to diabetic
animals enhanced the depressed activity of catalase (by 35%,
p<0.05) in the cytoplasm of liver cells and mitochondrial GST
(by 20%, p<0.05) in comparison with diabetes, respectively
(Table 2).
Mitochondrial impairments under diabetes
30-day diabetes was accompanied by a considerable
impairment of mitochondrial respiratory activity. In the case of
succinate as a respiratory substrate, the ADP-stimulated
respiration rate V3 markedly decreased (by 25%, p<0.05) (Fig.
1A) and the acceptor control ratio (ACR) V3/V2 was also
diminished (by 25%, p<0.01) (Fig. 1B). We observed a drop in
the respiration rate V2 (by 20%, p<0.05) and the ADP-stimulated
respiration rate V3 (by 35%, p<0.05) with glutamate as substrate
(Fig. 1A). In this case, the ACR also decreased (by 20%,
p<0.05). Surprisingly, the phosphorylation coefficient ADP/O
















Blood glucose, [mg/dl] 105.3±1.9 522.7±67.8 b 468.3±72.0 b 405.3±60.4 b 492.5±45.5 b
Glycated haemoglobin, 
[mol fructose/g Hb] 2.7±0.3 6.1±0.3
a 5.6±0.6a 4.8±0.7a 6.1±0.8a
ALT, µkat/l 0.95±0.08 1.43±0.09b 0.99±0.05d 1.51±0.15b 1.32±0.19 
AST, µkat/l 1.09±0.05 1.21±0.03a 0.85±0.03b,e 1.52±0.06c 1.04±0.14 
Weight, kidney, [g/100 g b.w.] 3.25±0.14 5.55±0.17c 4.98±0.41a 4.14±0.30d 4.99±0.28b
Body weight (initial), [g] 155±6.9 167.9±6.5 175±10.1 180.8±6.8 172.5±8.4 
Body weight (final), [g] 190±8.9* 175±10.9 179.2±16.1 205±6.3 175.8±13.6 
a- statistically significant in comparison with control, p<0.05; b- statistically significant in comparison with control, p<0.01; 
c- statistically significant in comparison with control, p<0.001; d- statistically significant in comparison with diabetes, p<0.01; 
e- statistically significant in comparison with diabetes, p<0.001; *- statistically significant in comparison with initial body weight; 
n- the number of animals.
Table 1. Blood glucose, glycated haemoglobin, alanine aminotransferase (ALT) and aspartate aminotransferas (AST) activities and
animal body and kidney weights in normal and STZ-treated diabetic rats. Effect of succinate and melatonin administration.
The activity of the key enzyme of the Krebs cycle, KGDH,
rose (by 60%, p<0.05) (Fig. 2); probably, this reflected the
activation of protein degradation and amino acid turnover
during diabetes. Despite the substantial damage in respiratory
activity, the activity of SDH, respiratory complex II, did not
change (Fig. 2).
Succinate administration during diabetes in rats exerted a
protective effect on the liver mitochondrial function. We
observed an enhancement of the reduced ADP-stimulated
oxygen consumption rate V3 (by 25%, p<0.05 in comparison
with diabetic animals) (Fig. 1A), when we used succinate as
a respiratory substrate. The ACR considerably increased to
the control values (p<0.01 in comparison with diabetic
animals) (Fig. 1B). Similarly, succinate administration to
diabetic animals reversed the ADP-stimulated oxygen
consumption rate V3 (increased by 30%, p<0.05 in
comparison with diabetic animals) and completely reversed
the ARC value when mitochondria oxidized glutamate as a
substrate (Fig. 1A, 1B). Melatonin administration during
diabetes exerted a marked protective effect on the liver
mitochondria function, reversing the decreased respiration
rate V3 to the control values both for succinate-dependent
respiration (p<0.05 in comparison with diabetic animals) and
for glutamate-dependent respiration (p<0.01). Similarly, the
melatonin treatment of diabetic rats reversed the effect of
diabetes on the ACR value both for succinate-dependent
respiration and for glutamate-dependent respiration (Fig. 1A,
1B). The combined administration of melatonin and succinate
to diabetic animals also reversed the V3 rate value, and the
ACR value for both oxidizing substrates (Fig. 1A, 1B) and
only succinate administration prevented a significant KGDH
activation during diabetes (Fig. 2).
DISCUSSION
There is interest in determining whether antioxidants will
reduce mitochondria oxidative damage and prevent diabetic
complications (6). Excess ROS accumulation stimulates various
serine/threonine kinases, including IKKβ, JNK and PKCs, and
inflammatory signaling, resulting in reduced insulin signaling
cascade (insulin resistance) (7). The protective effect of
antioxidants (α-lipoic acid, N-acetyl-cysteine, melatonin) on
oxidative stress-induced insulin resistance relate to their ability
to preserve the intracellular redox balance or to block the
activation of stress-sensitive kinases.
Numerous studies have evaluated increased oxidative stress
in mitochondria, as well as alterations in mitochondrial
metabolism and function in different tissues under diabetes (9,
27). However, the results reported are controversial. Thus, it was
reported that 9 weeks after STZ-induction of diabetes in rats,
respiratory function of liver mitochondria declined as assessed
by the mitochondrial membrane potential and respiratory ratios,
succinate dehydrogenase and cytochrome C oxidase activities:
all of them were significantly augmented (27). However, a
decline in state 3 respiration in heart mitochondria was shown
only in diabetic animals exhibiting a marked reduction in body
weight (28). The data argue against hyperglycemia being a direct
cause of the decline in state 3 oxygen consumption observed in
cardiac mitochondria of type 1 diabetic rats (28). Moreira et al.
(29) similarly concluded that 4-week and 9-week STZ-induced
diabetes in rats was not accompanied by brain mitochondria
dysfunction (4-week diabetic rats showed even higher
mitochondrial respiratory chain enzymatic activities, compared
to control rats), suggesting that oxidative stress associated with
















[nmol/mg protein] 91.9±1.8 92.2±1.2 94.1±2.1 93.7±1.6 93.8±1.5 
PSH,  
[nmol/mg protein] 83.4±1.8 83.1±1.1 85.3±2.1 85.1±1.4 85.0±1.5 
PSSG,  
[nmol/mg protein] 0.12±0.03 0.18±0.03
a 0.13±0.03 0.18±0.02 0.24±0.03a
TBARS,  
liver homogenate,  
[nmol/mg protein] 
0.31±0.01 0.35±0.02 0.28±0.01d 0.24±0.01c,e 0.27±0.02d
TBARS,  
heart homogenate,  
[nmol/mg protein] 
0.32±0.02 0.39±0.02a 0.42±0.05 0.34±0.02d 0.48±0.03b,d
GST,  
[nmol CDNB/min/mg protein] 35.2±1.7 30.8±0.6
a 32.2±2.5 36.7±2.4d 29.4±2.2
a
GPx,  
[nmol GSH/min/mg protein] 466.5±6.4 478.0±38.9 466.3±35.8 480±21.9 430±55.8 
Catalase,  
liver cell cytoplasm,  
[µmol H2O2/min/mg protein] 
517.7±33.2 281.7±27.2c 350.6±36.4b 386.1±20.6b,d 342.9±44.8a
GSH, erythrocytes,  
 [mM] 1.8±0.4 1.4±0.3
a 1.0±0.1a 1.4±0.1 1.2±0.1a
a- statistically significant in comparison with control, p<0.05; b- statistically significant in comparison with control, p<0.01; 
c- statistically significant in comparison with control, p<0.001; d- statistically significant in comparison with diabetes, p<0.05; 
e- statistically significant in comparison with diabetes, p<0.01; n- the number of animals. 
Table 2. The total (TSH) and protein (PSH) thiol groups, mixed glutathione-protein disulfides (PSSG), lipid peroxidation product
levels and antioxidative enzyme activities in rat liver cell mitochondria under diabetes. Effects of succinate and melatonin
administration.
physiology. Recently it was shown that glycated LDL, which
accumulates in patients with diabetes, increased ROS production
by mitochondria and attenuated the activities of key enzymes in
a mitochondrial electron-transport chain (30).
In the current experiments, we observed a considerable
impairment of rat liver mitochondria function during diabetes,
concomitant with liver damage. Significant diminishing of the
ADP-depended oxygen consumption rate V3 and impairment of
the coupling oxidation and phosphorylation processes in liver
mitochonria (the ACR values decreased) without changes in the
efficacy of oxygen consumption (the ADP/O did not change
during diabetes) were shown. 30-day diabetes resulted in an
increase of animal growth retardation, absolute and relative
kidney weight (Table 1), and in typical signs of elevated
oxidative stress. In rat liver mitochondria, diabetes was
accompanied by marked impairments of metabolism: we
observed a significant activation of KGDH, a key enzyme of the
Krebs cycle, without changes in SDH activity. At the same time
we did not observe alterations in the mitochondrial thiol group
levels, or in the mitochondrial membrane potential (data not
shown) as a result of diabetes. The reduction of the oxygen
consumption rate V3 with glutamate or succinate as substrates,
with KGDH or SDH activity diminution being unobserved,
could be explained either by impaired substrate oxidation in the
electron-transport chain or by reduced H+ translocation through
the inner mitochondrial membrane.
We observed some beneficial effects of the melatonin and
succinate administration on the complications of diabetes. In our
experiments, the melatonin administration had no effect on
diabetic growth retardation but partially prevented diabetic
increase of kidney weight. Other authors demonstrated that
melatonin supplementation to hamsters, rats, and mice reduced
their body weight and the mass of white adipose tissue (31).
Succinate-treated diabetic animals showed decreased ALT and
AST blood plasma activities in comparison with diabetic group
values. Melatonin treatment prevented GST inactivation and
succinate treatment prevented KGDH activation under diabetes.
The more important thing is that melatonin, as well as succinate
administration to diabetic animals improved the mitochondrial
physiology, i.e. increased the respiration rate of isolated rat liver
mitochondria and prevented a loss of respiratory control,
increasing the acceptor control ratio value. Generally, the
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Fig. 1. Parameters of respiratory activity of liver mitochondria in
normal and streptozotocin-treated diabetic rats. Effect of
succinate and melatonin administration: substrate-dependent
respiration rate V2 and ADP-stimulated respiration rate V3 (A) as
well as acceptor control ratio (V3/V2) and coefficient of
phosphorylation ADP/O (B). Glutamate (Glu) and succinate
(succ) were used as respiratory substrates. Data for 8-10 rats in
each group are presented as a mean ±S.E.M. The standard
unpaired Student t test was used for the comparison of the data.
* - statistically significant in comparison with control, p<0.05;
** - statistically significant in comparison with control, p<0.01;
# - statistically significant in comparison with diabetes, p<0.05;
## - statistically significant in comparison with diabetes, p<0.01;
###- statistically significant in comparison with diabetes,
p<0.001.
Fig. 2. Activities of a- ketoglutarate dehydrogenase (KGDH) and
succinate dehydrogenase (SDH) of liver mitochondria in normal
and streptozotocin-treated rats. Effect of succinate and
melatonin administration. Data for 8-10 rats in each group are
presented as a mean ±S.E.M. The standard unpaired Student 
t test was used for the comparison of data.* - statistically
significant in comparison with control, p<0.05; ** - statistically
significant in comparison with control, p<0.01; # - statistically
significant in comparison with diabetes, p<0.05; ## - statistically
significant in comparison with diabetes, p<0.01; ###-
statistically significant in comparison with diabetes, p<0.001.
simultaneous administration of melatonin and succinate to
diabetic rats did not show any additional beneficial effect in
comparison with the melatonin or succinate injections.
Succinate and its mitochondrial metabolites may participate
in triggering of insulin release by pancreatic islets (32). By
acting as ligands for appropriate receptors, succinate and α-
ketoglutarate have unexpected signaling functions beyond their
traditional roles in the regulation of energy homeostasis and
cellular metabolism (33). Mitochondrial oxidation of succinate
in isolated diabetic rat hepatocytes and succinate carbon
incorporation into proteins were markedly lowered, probably
due to impairment in the Krebs cycle activity (34). At the same
time we observed a significant activation of α-ketoglutarate
dehydrogenase in hepatic mitochondria of diabetic rats.
Melatonin exhibits a variety of biological activities,
including antioxidative protection of cells and anti-inflammatory
functions (35, 36). The highest intracellular concentration of
melatonin seems to be in mitochondria (37), which suggests its
involvement in regulation of mitochondrial function. Based on
the observations that melatonin treatment does not measurably
influence food intake and only has a limited impact on the
physical activity, the weight loss promoting effect of melatonin
must be attributed to alterations in energy metabolism, i.e.
increased energy expenditure induced by melatonin (31).
Uncoupling action of melatonin on oxidative phosphorylation in
isolated mitochondria has been observed by Lopez et al. (38).
We demonstrated this mild uncoupling effect of melatonin in
experimental rat model (39).
Melatonin influences insulin secretion, with this effect being
mediated by specific high-affinity, pertussis-toxin-sensitive G-
protein coupled receptors MT (1) as well MT (2) in pancreatic
islets (40). At the same time the reduced insulin levels in type 1
diabetes (streptozotocin-induced rat model of diabetes)
associated with higher melatonin concentrations in the blood and
elevated insulin levels observed in type 2 diabetes are associated
with reduced melatonin levels (40). The results suggest that a
melatonin-insulin antagonism may exist (41). It was shown
earlier that melatonin inhibits glucose-induced insulin secretion
in isolated rat islets without interfering with glucose metabolism
(42). Peschke et al. pointed out the fact that melatonin protects
the β-cells against functional overcharge and, consequently,
hinders the development of type 2 diabetes (43). The high
concentrations of blood plasma melatonin found in type 1
diabetes are supposed to be beneficial for preventing diabetic
lesions. At the same time the possible effect of melatonin on
insulin secretion by pancreatic islets should be verified.
Melatonin directly inhibits the mitochondrial permeability
transition pore in a dose-dependent manner (IC50=0.8 µM) in rat
liver mitoplasts; this inhibition may contribute to melatonin’s
anti-apoptotic effects during transient brain ischemia (44). The
combination of an antioxidant, melatonin, and a PARP inhibitor,
nicotinamide, caused an essential reversal of biochemical
alterations in diabetic neuropathy (45). The results of our study
suggest that the antioxidant melatonin and the energetic
substrate succinate, being signaling molecules, may be useful for
the pharmacotherapy of diabetic complications.
In summary, the data support an important role of
mitochondria dysfunction in the development of liver injury
during diabetes as well as the possibility of corrections of
mitochondrial disorders by melatonin and succinate. The
mechanism of mitochondrial dysfunction might be impairment
of cellular and mitochondrial redox-balance, changes of
mitochondrial metabolism, damage of the mitochondrial
membrane and components of the electron-transport chain.
Succinate, an energetic mitochondrial substrate, and melatonin,
a powerful antioxidant, effectively prevented the diabetic lesions
of rat liver mitochondria and should be considered as effectors
regulating mitochondria function. The effects of melatonin
might be due to both its radical scavenging properties, its
signaling effects and its interaction with complexes of the
respiratory chain.
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